abbvie.com - ABBV EV/Sales Multiple

Leveraging its impeccable authority in biotechnology, the GURU.Markets EV/Revenue chart clearly demonstrates the fundamental resilience of AbbVie Inc. (ABBV). The 8655.19 level captures the current state of the asset, which is supported by a powerful scientific staff. Meanwhile, the holding's pricing policy is currently transforming, shifting from aggressive pricing power toward flexible discounts due to the expiration of patent protection.
AbbVie Corp. - analytical breakdowns and key metrics (ABBV)

AbbVie Inc. (ABBV) is scaling new therapeutic pipelines to offset the loss of patent protection for legacy drugs. The EV/Sales valuation multiple measures business value by calculating the sum of market capitalization and net debt relative to revenue, eliminating the impact of financing structure on the assessment of cash flow generation efficiency. The trend in this EV/Sales ratio confirms margin resilience despite high R&D expenditures, determining the fundamental value of the assets.